{'output': [['Spark Therapeutics', 'COMP', 'Charge', '$850,000', 'ECON_INDICATOR'], ['Spark Therapeutics', 'COMP', 'Announce', 'Luxturna', 'PRODUCT'], ['Luxturna', 'PRODUCT', 'Approve', 'FDA', 'ORG/GOV'], ['Luxturna', 'PRODUCT', 'Treat', 'inherited retinal disease', 'CONCEPT'], ['inherited retinal disease', 'CONCEPT', 'Cause', 'defects in RPE65', 'CONCEPT'], ['defects in RPE65', 'CONCEPT', 'Tell', 'cells to produce enzyme', 'CONCEPT'], ['enzyme', 'CONCEPT', 'Critical', 'normal vision', 'CONCEPT'], ['Spark Therapeutics', 'COMP', 'Shares', 'rise', 'ECON_INDICATOR'], ['FDA', 'ORG/GOV', 'Approval', 'Luxturna', 'PRODUCT']]}